Same Mutation, Different Fate
When MRD testing evolves from a numerical readout into a definition of clonal behavior, it becomes what clinicians have needed all along: a tool that informs action, not just detection.
Zivjena Vucetic
A physician-scientist with more than 15 years of experience in diagnostics and emerging platforms, Zivjena Vucetic M.D., Ph.D. has directed medical and scientific strategies that move technologies from discovery to clinical settings, building regulatory confidence and supporting adoption across multiple therapeutic areas.
Prior to Mission Bio, Dr. Vucetic most recently served as Chief Medical Officer and Senior Vice President at Beckman Coulter Diagnostics, where she directed medical strategy across a multibillion-dollar global portfolio and advanced blood-based biomarker programs in Alzheimer’s and other neurodegenerative diseases. At Karius, she built the clinical and regulatory foundation for an infectious disease sequencing test that achieved FDA Breakthrough Device designation. She has also held leadership roles at Clinical Genomics, Ortho Clinical Diagnostics and Fujirebio Diagnostics, guiding end-to-end validation, payer engagement, and publication strategy while building strong partnerships with pharma and academic consortia.